Pulmonary arterial hypertension in connective tissue disease;Hypertension artérielle pulmonaire associée aux connectivites

Revue des Maladies Respiratoires

Volumn 23, Issue SUPPL. 4, 2006, Pages

  Cottin, V ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b LOUIS PRADEL HOSPITAL   (France)

Author keywords

Connective tissue disease; Pulmonary arterial hypertension; Systemic lupus erythematosus; Systemic sclerosis

Indexed keywords

BOSENTAN; ILOPROST; IMMUNOSUPPRESSIVE AGENT; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; UNIPROST; ANTIHYPERTENSIVE AGENT; AUTOANTIBODY;

ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DYSPNEA; ECHOCARDIOGRAPHY; HISTOPATHOLOGY; HUMAN; HYPOXEMIA; PREVALENCE; PULMONARY HYPERTENSION; VENOUS THROMBOEMBOLISM; IMMUNOLOGY; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; MIXED CONNECTIVE TISSUE DISEASE; PHYSIOLOGY; PROGNOSIS; RAYNAUD PHENOMENON; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THROMBOEMBOLISM;

ANTIHYPERTENSIVE AGENTS; AUTOANTIBODIES; CONNECTIVE TISSUE DISEASES; HUMANS; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIXED CONNECTIVE TISSUE DISEASE; PROGNOSIS; PULMONARY DIFFUSING CAPACITY; PULMONARY FIBROSIS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; THROMBOEMBOLISM;

EID: 33750334225     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1019/20064119     Document Type: Article

References (88)

1. Humbert M, Sitbon O, Simonneau G : Treatment of pulmonary arterial hypertension. N Engl J Med 2004 ; 351 : 1425-36.
2. Fishman AP : Primary pulmonary arterial hypertension: a look back. J Am Coll Cardiol 2004 ; 43 : 2S-4S.
3. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A : Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004 ; 43 : 5S-12S.
4. Montani D, Jais X, Sitbon O, Capron F, Simonneau G, Humbert M : Hypertension artérielle pulmonaire. Rev Mal Respir 2005 ; 22 : 651-66.
5. Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C : The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005 ; 52 : 2125-32.
6. Hesselstrand R, Ekman R, Eskilsson J, Isaksson A, Scheja A, Ohlin AK, Akesson A : Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology (Oxford) 2005 ; 44 : 366-71.
7. Montani D, Yaïci Y, Jaïs X, Sztrymf B, Cabrol S, Hamid A, Parent F, Sitbon O, Dartevelle P, Simonneau G, Humbert M : Hypertension artérielle pulmonaire. Encycl Med Chir (Paris-France) 2006 : 6024-A-90.
8. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G : Pulmonary Arterial Hypertension in France: Results from a National Registry. Am J Respir Crit Care Med 2006 ; 173 : 1023-1030.
9. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM : Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004 ; 43 : 25S-32S.
10. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM : Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998 ; 101 : 927-34.
11. Yokoi T, Tomita Y, Fukaya M, Ichihara S, Kakudo K, Takahashi Y : Pulmonary hypertension associated with systemic lupus erythematosus: predominantly thrombotic arteriopathy accompanied by plexiform lesions. Arch Pathol Lab Med 1998 ; 122 : 467-70.
12. Yousem SA : The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990 ; 21 : 467-74.
13. Fujita J, Yoshinouchi T, Ohtsuki Y, Tokuda M, Yang Y, Yamadori I, Bandoh S, Ishida T, Takahara J, Ueda R : Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001 ; 60 : 281-3.
14. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, Du Bois RM : Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002 ; 165 : 1581-6.
15. Dao P, Montani D, Duong-Quy S, Dinh-Xuan AT : Signalisation cellulaire et physio pathologie de l'hypertension artérielle pulmonaire. Rev Mal Respir 2006 ; 23 : 3S75-83.
16. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M : Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004 ; 43 : 13S-24S.
17. Mukerjee D, Yap LB, Ong V, Denton CP, Howells K, Black CM, Coghlan JG : The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension. Ann Rheum Dis 2004 ; 63 : 1627-31.
18. Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J : Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol 2002 ; 29 : 2379-81.
19. Tew MB, Arnett FC, Reveille JD, Tan FK : Mutations of bone morphogenetic protein receptor type II are not found, in patients with pulmonary hypertension and underlying connective tissue diseases. Arthritis Rheum 2002 ; 46 : 2829-30.
20. Satoh T, Kimura K, Okano Y, Hirakata M, Kawakami Y, Kuwana M : Lack of circulating autoantibodies to bone morphogenetic protein receptor-II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension. Rheumatology (Oxford) 2005 ; 44 : 192-6.
21. Preston IR, Hill NS : Evaluation and management of pulmonary hypertension in systemic sclerosis. Curr Qpin Rheumatol 2003 ; 15 : 761-5.
22. Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF : Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005 ; 26 : 1110-8.
23. Mouthon L, Guillevin L, Humbert M : Pulmonary arterial hypertension: an autoimmune disease? Eur Respir J 2005 ; 26 : 986-8.
24. Tamby MC, Chanseaud Y, Humbert M, Fermanian J, Guilpain P, Garcia-de-la-Pena-Lefebvre P, Brunet S, Servettaz A, Weill B, Simonneau G, Guillevin L, Boissier MC, Mouthon L : Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005 ; 60 : 765-72.
25. Sanchez O, Humbert M, Sitbon O, Simonneau G : Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999 ; 54 : 273-7.
26. Roncoroni AJ, Alvarez C, Molinas F : Plexogenic arteriopathy associated with pulmonary vasculitis in systemic lupus erythematosus. Respiration 1992 ; 59 : 52-6.
27. Kishida Y, Kanai Y, Kuramochi S, Hosoda Y : Pulmonary venoocclusive disease in a patient with systemic lupus erythematosus. J Rheumatol 1993 ; 20 : 2161-2.
28. Tanoue LT : Pulmonary hypertension in the collagen vascular diseases. Semin Respir Crit Care Med 2003 ; 24 : 287-96.
29. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, Kahan A, Cabane J, Frances C, Launay D, Mouthon L, Allanore Y, Tiev KP, Clerson P, de Groote P, Humbert M : Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005 ; 52 : 3792-800.
30. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, Black CM, Coghlan JG : Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003 ; 62 : 1088-93.
31. Hachulla E, Gressin V, Guillevin L, de Groote P, Cabane J, Carpentier P, Frances C, Kahan A, Humbert M : L'hypertension artérielle pulmonaire associée à la sclérodermie systémique : proposition d'un algorithme échocardiographique de dépistage pour un diagnostic précoce (ItinérAIR-Sclérodermie). Rev Med Interne 2004 ; 25 : 340-7.
32. Scorza R, Caronni M, Bazzi S, Nador F, Beretta L, Antonioli R, Origgi L, Ponti A, Marchini M, Vanoli M : Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci 2002 ; 966 : 238-46.
33. Steen V, Medsger TA, Jr : Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003 ; 48 : 516-22.
34. Ulanet DB, Wigley FM, Gelber AC, Rosen A: Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension. Arthritis Rheum 2003 ; 49 : 85-92.
35. Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC : Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003 ; 124 : 2098-104.
36. Chang B, Wigley FM, White B, Wise RA : Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003 ; 30 : 2398-405.
37. Steen V : Advancements in diagnosis of pulmonary arterial hypertension in scleroderma. Arthritis Rheum 2005 ; 52 : 3698-700.
38. Poormoghim H, Lucas M, Fertig N, Medsger TA, Jr : Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000 ; 43 : 444-51.
39. Badesh DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, McLaughlin VV : Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004 ; 126 : 35s-62s.
40. Sanchez O, Humbert M, Sitbon O, Nunes H, Garcia G, Simonneau G : Hypertension artérielle pulmonaire associée aux connectivites. Rev Med Interne 2002 ; 23 : 41-54.
41. Allanore Y, Borderie D, Meune C, Cabanes L, Weber S, Ekindjian OG, Kahan A : N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 2003 ; 48 : 3503-8.
42. D'Andrea A, Stisi S, Bellissimo S, Vigorito F, Scotto di Uccio F, Tozzi N, Moscato F, Pezzullo E, Calabro R, Scherillo M : Early impairment of myocardial function in systemic sclerosis: non-invasive assessment by Doppler myocardial and strain rate imaging. Eur J Echocardiogr 2005 ; 6 : 407-18.
43. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin W, Robbins IM, Groves BM, Shapiro S, Medsger TA, Jr : Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000 ; 132 : 425-34.
44. McLaughlin W, Genthner DE, Panella MM, Hess DM, Rich S : Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999 ; 130 : 740-3.
45. Klings ES, Hill NS, Ieong MH, Simms RW, Korn JH, Farber HW : Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum 1999 ; 42 : 2638-45.
46. Strange C, Bolster M, Mazur J, Taylor M, Gossage JR, Silver R : Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest 2000 ; 118 : 1077-82.
47. Humbert M, Sanchez O, Fartoukh M, Jagot JL, Le Gall C, Sitbon O, Parent F, Simonneau G : Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999 ; 13 : 1351-6.
48. Farber HW, Graven KK, Kokolski G, Korn JH : Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J Rheumatol 1999 ; 26 : 1195-6.
49. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G : Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002 ; 346 : 896-903.
50. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ : Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001 ; 358 : 1119-23.
51. Joglekar A, Tsai FS, McCloskey DA, Wilson JE, Seibold JR, Riley DJ : Bosentan in pulmonary arterial hypertension secondary to scleroderma. J Rheumatol 2006 ; 33 : 61-8.
52. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C : Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004 ; 50 : 3985-93.
53. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR : Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004 ; 169 : 441-7.
54. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G : Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005 ; 353 : 2148-57.
55. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, Westwood MA, Stefanidis A, Ng LL, Pennell DJ, Mohiaddin RH, Nihoyannopoulos P, Gibbs JS : Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 2005 ; 171 : 1292-7.
56. Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E : Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. Ann Intern Med 2003 ; 139 : 871-3.
57. Fries R, Shariat K, von Wilmowsky H, Bohm M : Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005 ; 112 : 2980-5.
58. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ : Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002 ; 165 : 800-4.
59. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W : Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002 ; 347 : 322-9.
60. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J : Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004 ; 25 : 2243-78.
61. Pigula FA, Griffith BP, Zenati MA, Dauber JH, Yousem SA, Keenan RJ : Lung transplantation for respiratory failure resulting from systemic disease. Ann Thorac Surg 1997 ; 64 : 1630-4.
62. Rosas V, Conte JV, Yang SC, Gaine SP, Borja M, Wigley FM, White B, Orens JB : Lung transplantation and systemic sclerosis. Ann Transplant 2000 ; 5 : 38-43.
63. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, Black CM : Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001 ; 40 : 453-9.
64. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE : Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003 ; 123 : 344-50.
65. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CR Smith CJ, Black CM, Coghlan JG : Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (in press) 2006.
66. Pan TL, Thumboo J, Boey ML : Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000 ; 9 : 338-42.
67. Shen JY, Chen SL, Wu YX, Tao RQ, Gu YY, Bao CD, Wang Q : Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 1999 ; 18 : 147-51.
68. Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Hughes GR : Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990 ; 17 : 1292-8.
69. Simonson JS, Schiller NB, Petri M, Hellmann DB : Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1989 ; 16 : 918-25.
70. Li EK, Tam LS : Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 1999 ; 26 : 1923-9.
71. Perez HD, Kramer N : Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. Semin Arthritis Rheum 1981 ; 11 : 177-81.
72. Winslow TM, Ossipov MA, Fazio GP, Simonson JS, Redberg RF, Schiller NB : Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J 1995 ; 129 : 510-5.
73. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, Fernandez L, Ponce de Leon S : Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989 ; 68 : 353-65.
74. Gussin HA, Ignat GP, Varga J, Teodorescu M : Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2001 ; 44 : 376-83.
75. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N : Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002 ; 29 : 282-7.
76. Karmochkine M, Wechsler B, Godeau P, Brenot F, Jagot JL, Simonneau G : Improvement of severe pulmonary hypertension in a patient with SLE. Ann Rheum Dis 1996 ; 55 : 561-2.
77. Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin LJ, Loyd JE : Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000 ; 117 : 14-8.
78. Hanta I, Demir M, Akpinar O, Kocabas A, Ozbek S : Is sildenafil effective in secondary pulmonary hypertension due to systemic lupus erythematosus? A case report. Clin Rheumatol 2005 ; 24 : 671-2.
79. Levy RD, Guerraty AJ, Yacoub MH, Loertscher R : Prolonged survival after heart-lung transplantation in systemic lupus erythematosus. Chest 1993 ; 104 : 1903-5.
80. Wiener-Kronish JP, Solinger AM, Warnock ML, Churg A, Ordonez N, Golden JA : Severe pulmonary involvement in mixed connective tissue disease. Am Rev Respir Dis 1981 ; 124 : 499-503.
81. Burdt MA, Hoffman RW Deutscher SL, Wang GS, Johnson JC, Sharp GC : Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999 ; 42 : 899-909.
82. Sullivan WD, Hurst DJ, Harmon CE, Esther JH, Agia GA, Maltby JD, Lillard SB, Held CN, Wolfe JF, Sunderrajan EV : A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 1984 ; 63 : 92-107.
83. Alpert MA, Goldberg SH, Singsen BH, Durham JB, Sharp GC, Ahmad M, Madigan NP, Hurst DP, Sullivan WD : Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation 1983 ; 68 : 1182-93.
84. Yaqub S, Moder KG, Lacy MQ : Severe, reversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyositis. Mayo Clin Proc 2004 ; 79 : 687-9.
85. Dawson JK, Goodson NG, Graham DR, Lynch MP : Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology (Oxford) 2000 ; 39 : 1320-5.
86. Handa T, Nagai S, Kawabata D, Nagao T, Takemura M, Kitaichi M, Izumi T, Mimori T, Mishima M : Long-term clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Intern Med 2005 ; 44 : 319-25.
87. Bertoni M, Niccoli L, Porciello G, Storri L, Nannini C, Manes A, Palazzini M, Galie N, Cantini F : Pulmonary hypertension in primary Sjogren's syndrome: report of a case and review of the literature. Clin Rheumatol 2005 ; 24 : 431-4.
88. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, Israel-Biet D, Court-Fortune I, Valeyre D, Cordier JF : and the Groupe d'Etude et de Recherche sur les Maladies «Orphelines» Pulmonaires (GERM"O"P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005 ; 26 : 586-93